Poillet-Perez, Laura
Sharp, Daniel W.
Yang, Yang http://orcid.org/0000-0001-8963-658X
Laddha, Saurabh V. http://orcid.org/0000-0002-8781-9478
Ibrahim, Maria
Bommareddy, Praveen K. http://orcid.org/0000-0003-0089-8693
Hu, Zhixian Sherrie
Vieth, Joshua
Haas, Michael
Bosenberg, Marcus W.
Rabinowitz, Joshua D. http://orcid.org/0000-0002-1247-4727
Cao, Jian http://orcid.org/0000-0003-3424-6802
Guan, Jun-Lin http://orcid.org/0000-0001-8720-8338
Ganesan, Shridar
Chan, Chang S.
Mehnert, Janice M.
Lattime, Edmund C. http://orcid.org/0000-0003-4945-7741
White, Eileen http://orcid.org/0000-0003-2961-3065
Article History
Received: 25 May 2020
Accepted: 4 August 2020
First Online: 18 September 2020
Change Date: 16 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-021-00252-2
Competing interests
: E.W. is co-founder of Vescor Therapeutics and is a consultant for Novartis. S.G. has consulted for Roche, Merck, Novartis, Foundation Medicine and Foghorn Therapeutics. The other authors declare no competing interests.